Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR.

Julien Mazieres; Louis Fehrenbacher; Achim Rittmeyer; Alexander I. Spira; Keunchil Park; David A. Smith; Angel Artal-Cortes; Conrad R. Lewanski; Fadi S. Braiteh; Jing Yi; Pei He; Marcin Kowanetz; Daniel Waterkamp; Marcus Ballinger; Daniel S. Chen; Alan Sandler; Johan F. Vansteenkiste

doi:10.1200/jco.2016.34.15_suppl.9032

Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.9032 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 9032-9032 ◽

Cited By ~ 14

Author(s):

Julien Mazieres ◽

Louis Fehrenbacher ◽

Achim Rittmeyer ◽

Alexander I. Spira ◽

Keunchil Park ◽

...

Keyword(s):

Phase Ii ◽

Treatment Effects ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Modified Recist

Download Full-text

Evaluation of non-classical response by immune-modified RECIST and efficacy of atezolizumab beyond disease progression in advanced NSCLC: Results from the randomized Phase II study POPLAR

Annals of Oncology ◽

10.1093/annonc/mdx091.016 ◽

2017 ◽

Vol 28 ◽

pp. ii35 ◽

Cited By ~ 2

Author(s):

A. Artal-Cortes ◽

J. Mazieres ◽

L. Fehrenbacher ◽

A. Rittmeyer ◽

A.I. Spira ◽

...

Keyword(s):

Disease Progression ◽

Phase Ii ◽

Advanced Nsclc ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Modified Recist

Download Full-text

Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab vs. docetaxel in patients with advanced NSCLC (POPLAR)

Pneumologie ◽

10.1055/s-0036-1572212 ◽

2016 ◽

Vol 70 (S 01) ◽

Author(s):

A Rittmeyer ◽

A Spira ◽

K Park ◽

J Mazieres ◽

J Vansteenkiste ◽

...

Keyword(s):

Phase Ii ◽

Advanced Nsclc ◽

Phase Ii Study ◽

Predictive Biomarker ◽

Randomized Phase Ii

Download Full-text

Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study

Case Medical Research ◽

10.31525/ct1-nct04095208 ◽

2019 ◽

Author(s):

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Phase Ii Study ◽

Proof Of Concept ◽

Randomized Phase Ii ◽

Metastatic Soft Tissue Sarcoma

Download Full-text

Randomized Phase II Study of Bortezomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Multiple Myeloma.

Case Medical Research ◽

10.31525/ct1-nct04277845 ◽

2020 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii

Download Full-text

Faculty Opinions recommendation of Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717962446.793468191 ◽

2012 ◽

Author(s):

Steven Le Gouill ◽

Cyrille Touzeau

Keyword(s):

Multiple Myeloma ◽

Phase Ii ◽

Induction Therapy ◽

Phase Ii Study ◽

Randomized Phase Ii

Download Full-text

Faculty of 1000 evaluation for Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718021759.793480257 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Progesterone Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii ◽

Positive Breast Cancer

Download Full-text

Faculty of 1000 evaluation for A Double-Blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-L-Carnitine in the Prevention of Sagopilone-Induced Peripheral Neuropathy.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718136956.793486581 ◽

2013 ◽

Author(s):

Steve Plaxe ◽

Kristy Ward

Keyword(s):

Peripheral Neuropathy ◽

Phase Ii ◽

Phase Ii Study ◽

Double Blind ◽

Safety And Efficacy ◽

Randomized Phase Ii

Download Full-text

Faculty Opinions recommendation of Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734565867.793581155 ◽

2020 ◽

Author(s):

David Potter

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Neoadjuvant Therapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Estrogen Receptor Positive

Download Full-text

Randomized Phase II Study of CPT-11 vs PTX; +/- S1 in Advanced Gastric Cancer Refractory to S1 or S1 + Platinum

Annals of Oncology ◽

10.1093/annonc/mdu165.44 ◽

2014 ◽

Vol 25 ◽

pp. ii28

Author(s):

Goto Masahiro ◽

Imamura Hiroshi ◽

Kawase Tomono ◽

Kimura Yutaka ◽

Ueda Shugo ◽

...

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii

Download Full-text

Randomized Phase Ii Study of S-1 Plus Oral Leucovorin (Sl) Versus Sl Plus Oxaliplatin (Sol) Versus S-1 Plus Cisplatin (Sp) in Patients with Advanced Gastric Cancer (Agc):Updated Overall Survival Data

Annals of Oncology ◽

10.1093/annonc/mdu334.10 ◽

2014 ◽

Vol 25 ◽

pp. iv213 ◽

Cited By ~ 1

Author(s):

K. Yamaguchi ◽

S. Hironaka ◽

N. Sugimoto ◽

T. Moriwaki ◽

Y. Komatsu ◽

...

Keyword(s):

Gastric Cancer ◽

Overall Survival ◽

Advanced Gastric Cancer ◽

Phase Ii ◽

Survival Data ◽

Phase Ii Study ◽

Randomized Phase Ii

Download Full-text